18F-FDG PET/CT of advanced gastric carcinoma and association of HER2 expression with standardized uptake value

Document Type : Original Article


1 Department of Nuclear Medicine, Konyang University College of Medicine, Daejeon, Korea

2 Department of Pathology, Konyang University College of Medicine, Daejeon, Korea


Objective(s): Expression of HER2 in gastric carcinoma has direct prognostic and therapeutic implications in patient management. The aim of this study is to determine whether a relationship exists between standardized uptake value
(SUV) and expression of HER2 in advanced gastric carcinoma.
Methods: We analyzed the 18F-FDG PET/CT results of 109 patients that underwent gastrectomy for advanced gastric carcinoma. The 18F-FDG PET/CT imaging was requested at the initial staging before surgery. The examinations were evaluated semi-quantitatively, with calculation of maximum standardized uptake values (SUVmax). The clinicopathologic factors, including HER2 overexpression, were determined from tissue obtained from the primary tumor.
Metabolic and clincopathologic parameters were correlated using a t-test, one way ANOVA and chi-square test.
Results: Immunohistochemically, 26 patients (23.8%) showed HER2 overexpression. This overexpression was significantly associated with high SUV level (P=0.02). The SUV level was significantly correlated with tumor size
(P=0.02) and differentiation (P<0.001), and Lauren histologic type (P=0.04).
Multivariate analysis showed HER2 overexpression, large tumor size, and differentiation (P=0.022, P=0.002, P<0.001) were significantly correlated with the high level of SUV in advanced gastric carcinoma. No association was found between SUV and T stage and lymph node metastasis. A receiver-operating characteristic curve demonstrated a SUVmax of 3.5 to be the optimal cutoff for predicting HER2 overexpression (sensitivity; 76.9%, specificity; 60.2%).
Conclusion: An association exists between high SUV and HER2 overexpression and 18F-FDG PET/CT could be a useful tool to predict the biological characteristics of gastric carcinoma.


  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12):2893-917.
  2. Park JM, Kim YH. Current approaches to gastric cancer in Korea. Gastrointest Cancer Res. 2008; 2(3):137-44.
  3. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 1990; 5(7):953-62.
  4. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007; 26(45): 6469-87.
  5. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009; 14(4):320-68.
  6. Jorgensen JT, Nielsen KV, Ejlertsen B. Pharmaco-diagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer. Oncologist. 2007; 12(4):397-405.
  7. Bongiorno PF, Whyte RI, Lesser EJ, Moore JH, Orringer MB, Beer DG. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarci-nomas. J Thorac Cardiovasc Surg. 1994; 107(2): 590-5.
  8. Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, et al. HER-2 profiling and targeting in prostate carcinoma. Cancer. 2002; 94(4): 980-6.
  9. Schuell B, Gruenberger T, Scheithauer W, Zielinski C, Wrba F. HER 2/neu protein expre-ssion in colorectal cancer. BMC Cancer. 2006; 6:123.
  10. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemo-therapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, random-ised controlled trial. Lancet. 2010; 376(9742): 687-97.
  11. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008; 49(3):480-508.
  12. Edge SB BD, Compton CC, Fritz AG, Greene FL, Trotti A, editor. AJCC cancer staging manual 7ed: New York, NY: Springer; 2010.
  13. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomog-raphy/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008; 38(4):250-8.
  14. Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, et al. Expression of glucose transporter-1 in human gastric carcin-oma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001; 92(3): 634-41.
  15. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 2003; 30(2):288-95.
  16. Han EJ CW, Chung YA et al. Comparision between FDG uptake and clinicopathologic and immun-ohistochemical parameters in pre-operative PET/CT Scan of primary gastric carcinoma. Nucl Med Mol Imaging. 2009; 42(1):26-34.
  17. Kim WS KY, Jang SJ, Kimm K, Jung MH. Glucose transporter 1 (GLUT1) expression is associated with intestinal type of gastric carcinoma. J Korean Med Sci. 2000; 15:420-4.
  18. Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med. 2006; 20(9): 597-604.
  19. Oh HH, Lee SE, Choi IS, Choi WJ, Yoon DS, Min HS, et al. The peak-standardized uptake value (P-SUV) by preoperative positron emission tomography-computed tomography (PET-CT) is a useful indicator of lymph node metastasis in gastric cancer. J Surg Oncol. 2011; 104(5):530-3.
  20. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg. 2004; 28(3):247-53.
  21. Lastraioli E, Romoli MR, Arcangeli A. Immunohistochemical biomarkers in gastric cancer research and management. Int J Surg Oncol. 2012; 2012:868645.
  22. Dang HZ, Yu Y, Jiao SC. Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis. World J Gastroenterol. 2012; 18(19): 2402-7.
  23. Sakai K, Mori S, Kawamoto T, Taniguchi S, Kobori O, Morioka Y, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst. 1986; 77(5):1047-52.
  24. Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review. Int J Cancer. 2012; 130(12):2845-56.
  25. Jorgensen JT HM. HER2 as a prognostic marker in gastric cancer - A systematic analysis of data from the literature. J Cancer. 2012; 3:137-44.